Longitudinal follow up of serological response in children treated for Chagas disease by Moscatelli, Guillermo et al.
RESEARCH ARTICLE
Longitudinal follow up of serological response
in children treated for Chagas disease
Guillermo MoscatelliID
1,2*, Samanta Moroni1,2, Facundo Garcı́a Bournissen1,2,
Nicolás González1, Griselda Ballering1, Alejandro Schijman3, Ricardo Corral1,
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Evaluation of therapeutic response in chronic Chagas disease is a major challenge, due to
prolonged persistence of Trypanosoma cruzi-specific antibodies, lack of sensitivity of para-
sitological tests, and need for long-term follow-up to observe negative seroconversion of
conventional serological tests (CS). The objective of this study was to evaluate F2/3-ELISA
serology, a promising early biomarker of therapeutic response, and T.cruzi Polymerase
chain reaction (PCR) for T. cruzi Deoxyribonucleic acid (DNA), for neonatal diagnosis and
evaluation of parasitemia after treatment.
Methods
Prospective cohort study, with three-year clinical, serological and parasitological follow-up
of pediatric Chagas disease patients treated with benznidazole. Serology was evaluated by
Enzyme-Linked ImmunoSorbent Assay (ELISA), Indirect hemagglutination (IHA) and F2/3-
ELISA; Parasitemia by microhematocrit (MH) and PCR.
Results
A cohort of 107 pediatric patients treated with benznidazole was enrolled in the study.
ELISA and IHA were initially reactive in 100% of patients, F2/3-ELISA serology was reactive
in 80% (86/107) and 91% (97/107) had detectable parasitemia. Seventy-six (71%) patients
completed at least 36 months of serological follow up after treatment. Although a similar
decreasing linear trend was observed for all serological tests, F2/3-ELISA presented earlier,
age dependent, negative seroconversion compared to CS. All patients reaching undetect-
able CS titers had previously seroreverted by F2/3-ELISA. All patients with persistently
decreasing antibody titers had negative PCRs throughout the follow up period. No new car-
diological lesions were observed during the 3 years follow-up period.
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Conclusions
The data reported here, using CS, F2/3 ELISA and PCR provide support for the efficacy of
benznidazole in congenital Chagas diseases. These results provide support for scaling up
of screening, diagnosis and access to benznidazole treatment.
Trial registration
ClinicalTrials.gov 0028/04 in the Research Council, Secretary of Health Buenos Aires city
Goberment.
Author summary
Evaluation of therapeutic response in chronic Chagas disease is a major challenge, particu-
larly in the early post-treatment phase, due to prolonged persistence of Trypanosoma
cruzi-specific antibodies and lack of sensitivity of available parasitological tests. The main
limitation in evaluating Chagas disease treatment response stems from the need for long-
term follow-up to observe negative seroconversion of conventional serological tests. New
biomarkers of cure are needed. We evaluated F2/3-ELISA, a promising early serological
marker of therapeutic response, and T.cruzi PCR for T.cruzi DNA, for neonatal diagnosis
and evaluation of parasitemia after treatment. F2/3-ELISA and PCR proved to be excellent
early markers of treatment response that correlate with ELISA and IHA but can identify
treatment response or failure at much earlier timepoints. This information can help
design future paediatric clinical trials in Chagas disease.
Introduction
Chagas disease (CD), or American trypanosomiasis, caused by Trypanosoma cruzi affects an
estimated 6–7 million people in Latin America [1], and has recently evolved into a global
health concern due to migration [2]. T.cruzi has a broad range of hosts, including wild and
domestic animals, and is primarily transmitted by infected haematophagous Triatominae
bugs. However, due to improved vector control and migration of infected people to urban
areas without the vector, presently the most common infection route is congenital [3].
CD features an initial acute phase with high parasitaemia. Clinical symptoms are variable
and decline spontaneously after some weeks but the majority of subjects are asymptomatic.
During this phase of the infection appropriate treatment can eliminate the parasite, leading to
rapid negative seroconversion. Patients who remain untreated will progress into an “indeter-
minate stage” with intermittent parasitemia but no overt clinical manifestations and, eventu-
ally, into a chronic phase characterized by low level parasitaemia and presence of anti-T.cruzi
antibodies.
The majority of chronic patients remain in the indeterminate stage, but approximately 30–
40% eventually develop cardiac or gastrointestinal complications in the long term [4]. Evalua-
tion of therapeutic response in chronic CD is a major challenge due to prolonged persistence
of T.cruzi-specific antibodies and low sensitivity of available parasitological tests [5,6]. Further-
more, no test currently in use (e.g. ELISA, IHA, PCR, etc) has been validated for long term fol-
low up of patients, as they were initially developed for diagnostic purposes.
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Use of conventional serological methods (CS) such as ELISA and IHA for follow-up after
treatment is widespread but has never been fully validated, and has proven unsuccessful in dem-
onstrating treatment response in most patients as total anti-T.cruzi antibodies may take years to
become negative [7]. However, pediatric trials for therapeutic markers are largely lacking.
The main limitations in evaluating treatment response for CD stems from the need for
long-term follow-up (years to decades) to observe negative seroconversion of CS tests. In this
context, new markers of cure are needed. Alternative early markers of cure have been sug-
gested, such as decrease of total anti-T.cruzi antibody titers (i.e. instead of negative seroconver-
sion) or use of non-conventional serological techniques [8,9] such as specific lytic anti-α-Gal
antibodies known as anti-F2/3 antibodies [5,10]. Similarly, polymerase chain reaction against
T.cruzi-DNA (PCR), has been proposed as a sensitive and specific method to detect parasite-
mia in newborns [11,12] and during follow-up after treatment [12,13].
The aim of this study was to describe, in a cohort of infants and children, serological and




Study protocol was reviewed by Research & Teaching Committee and the Bioethics Commit-
tee of the “Ricardo Gutiérrez” Children´s Hospital, and the Secretariat Committee for
Research Involving Human Subjects, World Health Organization (Geneva, Switzerland). Writ-
ten informed consent was obtained from legal guardians of the minors, as well as patient con-
sent or assent, as appropriate.
Study design
Prospective, cohort study of pediatric CD patients treated with benznidazole (S2).
Patients
Infants and children living in the City of Buenos Aires, Argentina, a non-endemic area for CD,
diagnosed at the Parasitology and Chagas Service, Children’s Hospital “Ricardo Gutierrez”
between 09/2003 and 10/2007. Patients with T.cruzi infection, less than 20 years old and previ-
ously untreated for CD were enrolled in the study if they had no cardiovascular, hepatic, neu-
rologic, endocrine, or other major systemic diseases and were not immunocompromised.
CD was diagnosed as positive parasitemia by microhematocrit (MH) in patients under 8
months [14] or, in older patients, if they had at least two reactive CS, ELISA (CS-ELISA), indi-
rect hemagglutination (IHA), or particle agglutination. Sera obtained by centrifugation for
serological assays were kept at -20˚C until analyzed.
F2/3-ELISA Chemiluminescent ELISA for detection of anti-F2/3 antibodies was performed
purified using F2/3 glycoconjugates [15] according to Almeida et al.
Serological results were expressed as the difference between the optical density value
recorded for each serum sample and the cut-off value of the assay.
Detection of T.cruzi-DNA by PCR was done in blood (2 mL) mixed with EDTA-guanidine
buffer [12,16].
Clinical and biochemical evaluation
Serology by CS-Elisa, IHA and F2/3-ELISA, were done at the initial visit and repeated at 7, 30
and 60 days of drug therapy, every 3 months during the first-year post-treatment and every 6
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months thereafter for the 36 months post treatment. MH for parasitemia was performed
weekly until negative in subjects with positive MH at diagnosis; PCR was carried out at diagno-
sis and at 7, 30 and 60 days of drug therapy, and 3, 6, 12, 24 and 36 months post treatment.
Although it was planned as an observational study with a 36 months follow-up, in a cohort
of patients we use available data along a longer follow-up, completing 96 months.
Laboratory evaluation (haematology, hepatology and renal function biochemical tests, and
Pregnancy test for females of childbearing potential.), electrocardiogram, and echocardiogram
were performed before and, at the end of treatment; Clinical evaluation was done at every visit,
and electrocardiogram and echocardiogram were repeated yearly during follow-up.
Treatment: benznidazole (100-mg tablets) was prescribed at 5–8 mg per kg, in two or three
daily doses for 60 days. Infants’ doses were provided as fractionated tablets prepared by a
research pharmacist and administered with milk. Medication was provided in monthly batches
and compliance was assessed by counting the remaining tablets at each visit. Adverse drug
reactions (ADRs) were evaluated through laboratory tests, clinical interrogation and physical
examination.
Statistical analysis
Continuous variables are presented as means with CI95% or medians and interquartile range,
and categorical variables as percentages.
The disappearance kinetics of serum antibodies were analyzed using survival analysis. Sig-
nificance levels for analysis were 0.05. Analyses were performed with R software v3.0 (R Core
Team 2018. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.
org/).
Results
Out of 127 pediatric Chagas disease patients screened, 107 patients were enrolled in the study
(Fig 1).
Demographic data are shown in Table 1.
All patients were asymptomatic at diagnosis, with normal electrocardiogram and echocar-
diogram, and no Chagas disease-associated pathology.
Treatment: Mean benznidazole dose was 6.4 mg/kg per day (range 5–8 mg/kg) in 2 divided
doses (n = 76) or 3 divided doses (n = 31). Mean treatment length was 60 days (CI95 59–61).
We observed good compliance on the basis of tablet counts and medication log review. A total
of 91/107 (85.0%) enrolled patients completed drug treatment. Benznidazole was well tolerated
and ADRs were mild, not requiring treatment suspension [17].
Patient retention during long term follow up was as follows: 92 (86%) at 3 months after
treatment, 86 (80.3%) at 12 months, 82 (76.6%) at 18 months, 80 (74.7%) at 24 months, 76
(71%) at 30 months and 76 (71%) at 36 months (Fig 1). In addition, we have completed follow-
up beyong the limit of the protocol for clinical reasons for 41 (38%) subjects at 72 months after
treatment.
Parasitological studies
Parasitemia was positive in 97/107 (90.6%) patients before treatment (84 by PCR, 8 by both
PCR and MH, and 5 by MH test). All 13 patients younger than 8 months of age had positive
MH, and 8/8 (100%) for whom PCR samples were available also had positive PCR (PCR sam-
ples were not available for 5 patients with positive MH). (Table 2).
In patients younger than 8 months MH test rapidly became negative after start of treatment;
in 10/13 (76.9%) MH was negative at 7 days of treatment (p<0.001, Fisher’s exact test) and the
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Fig 1. Flow diagram of children enrolled in the study and information about sides effects.
https://doi.org/10.1371/journal.pntd.0007668.g001
Table 1. Demographic data.
Residence in Buenos Aires n = 107 (100%)
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remaining 3 positive patients became MH negative within 30 days of treatment. Parasitological
response was evaluated by PCR in 102/107 patients (5 infants did not have enough sample for
PCR); PCR remained positive in 38/94 (40.4%) patients at 7 days of treatment, 4/91 (4.4%) at
30 days and 1/88 (1.1%) at end of treatment (Fisher’s exact test, p<0.001 for all comparisons
against baseline) (Table 2, PCR results during treatment follow up. Patients who became nega-
tive remained negative. Positive results are for patients who had not became negative before).
Serological studies
CS-Elisa and IHA were initially reactive in 107/107 (100%) of patients at diagnosis; F2/3-
ELISA was reactive in 105/106 (81.1%) (1 patient had no F2/3-ELISA samples at diagnosis).
Seventy-six patients completed at least 36 months serological follow up by both CS and F2/
3 ELISA. CS-ELISA, CS-IHA and F2/3-ELISA values were analyzed at each time point during
follow-up, stratified by patient age (Fig 2).
A progressive reduction was observed for CS-ELISA, CS-IHA and F2/3-ELISA (Fig 3).
Although kinetics showed a similar decreasing linear trend in all tests, F2/3-ELISA pre-
sented earlier negative seroconversion than CS (Table 3, Fig 4).
A total of 84.4% (38/45) patients under 2 years that completed 36 months of follow up with
both CS-ELISA and CS-IHA, 29 seroconverted (p<0.001 compared to baseline, Chi-squared
test), and 9 had decreases in antibody titers but failed to reach negative values during this fol-
low up period. Ten patients less than 2 years old were lost to follow up before negative
seroconversion.
Children over 2 years of age (62/107) showed a persistent decrease of antibodies titers in
CS; 4 patients became negative, all later than 32 months (Median time to conversion: 72
months, range 32–90). All patients with persistently decreasing antibody titers (even if still
positive) also had negative PCR throughout the follow up.
Out of 105 patients with initial positive F2/3-ELISA antibodies testing, 66 completed follow
up with this method. In this population 48/66 (72.7%) became negative during follow up
(p<0.001, Chi-squared test): 15 (33.3%) became negative at end of treatment, 9 (13.3%) at 6
months post-treatment, 5 (11.1%) at 9 months, 4 (8.9%) at 26 months, 9 (20%) at 36 months
and 6 (13.4%) at 42 months. The median age of patients who became negative on F2/3-ELISA
was 6,7 years (range: 10 days-19 years). On the other hand, the median age of the patients who
remained with the positive F2/3-ELISA throughout the follow-up was 11.3 years (range: 4.5
years-19 years).
All patients reaching undetectable CS titers had previously become negative by PCR and
F2/3-ELISA.
Table 2. PCR results during treatment follow up. Patients who became negative remained negative. Positive results
are for patients who had not became negative before.
Time of follow up n Positive result Percent (CI95)
0 102 92 90.2 (83.9–95.2)
7 days 94 38 40.4 (29.4–48.9)
30 days 91 4 4.4 (1.1–9.3)
60 days 88 1 1,1 (0.5–8.9)
5 months 81 2 2.5 (0–4.5)
8 months 78 2 2.6 (0.7–9.0)
12 months 77 2 2.6 (0.7–9.1)
24 months 74 1 1.3 (0.3–8.2)
36 months 74 1 1.3 (0.3–8.2)
https://doi.org/10.1371/journal.pntd.0007668.t002
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No cardiac alterations by electrocardiogram or echocardiogram were observed during fol-
low-up of any of the patients in the cohort.
A total of 74/76 (97.4%) patients had persistently negative PCR results at 3 years follow-up.
Two patients (3 months and 7 years old) showed persistently positive PCR and serology in all
samples during follow-up (Table 2). The mother of the 3 months old boy eventually acknowl-
edged that she had not administered the treatment to her infant, and a new round of benznida-
zole treatment was attempted with good response. The other 7 years old child received
benznidazole treatment appropriately and therefore was considered as treatment failure; a new
treatment with nifurtimox 10 mg/k/day for 60 days was indicated, with good response. Both
children showed negative PCR and a decrease in CS antibody titers in the 3 years of follow-up
after the second treatment.
Discussion
Two drugs are available for the treatment of CD: benznidazole and nifurtimox. The effective-
ness of these drugs, especially in the chronic stage of infection, is still a topic of debate due to
inconsistent results and a lack of early biomarkers of treatment response [18,19].
The treatment goals for T.cruzi infection are to eliminate the parasite and to decrease the
probability of clinical progression of the disease.
Several studies have suggested that the etiological treatment of CD leads to negative results
in non-conventional serological tests and/or the prevention of electrocardiographic and clini-
cal changes related to disease progression [19,20,21,22].
Fig 2. Individuals serological profiles versus time: for ELISA; for IHA, and for F2/3. Thick red line = smooth regression of the data. Horizontal blue
line = cut value.
https://doi.org/10.1371/journal.pntd.0007668.g002
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However, other studies are contradictory and indicate that when treatment is administered
during the chronic phase of the disease, the parasite is not completely eliminated, and the
progress of the disease is not interrupted; therefore, the complications of the infection are not
prevented [23,24,25,26,27]. Controversies still exist regarding the real effects of the drugs used
in human treatment on the clinical progression of CD, particularly in adults during the
chronic phase of the infection.
These contradictions are most likely caused by the use of different treatment regimens and/
or post-treatment evaluation protocols [28].
Here we present the parasitological and serological follow up of a large cohort of infants
and children, mainly infected by the transplacental route, treated with benznidazole in the
acute and early chronic phase of the infection. These patients were asymptomatic and without
Table 3. Median of survival time of antibody anti-T. cruzi.









0 to 2 m 6 2 (1-NA) 6 5 (5-NA) 5 1 (1-NA)
3m to 2y 32 14 (11–54) 32 26 (14–42) 32 5 (2–26)
3y to 12y 40 84 (84-NA) 40 90 (90-NA) 40 32 (26–36)
13y to 19y 29 78 (78-NA) 29 NA 29 36 (14–48)
IHA: indirect hemagglutination comercial kit; Tc-ELISA: comercial ELISA kit using Trypanosoma cruzi lysate antigen-coated microplates; F2/3-ELISA: in-house
chemiluminescent ELISA using F2/3 antigen-coated microplates; m: months; y: years; NA: not available.
https://doi.org/10.1371/journal.pntd.0007668.t003
Fig 3. Survival curve time to negative serology or PCR.
https://doi.org/10.1371/journal.pntd.0007668.g003
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cardiological involvement at the time of diagnosis and treatment and therefore treatment had
no demonstrable immediate clinical benefit. During the 3 years follow-up period, no new car-
diological lesions were observed. Further studies with longer follow-up are needed to confirm
these results. In this context, identification and validation of biomarkers in our large cohort of
congenital cases will enable the development of much needed new and improved treatments.
Our results also show a high rate of therapeutic response, as measured by different serologi-
cal tests and by T.cruzi-PCR. Treatment was well tolerated with mild adverse events as was
reported in a previous publication [17].
There are several choices to diagnose Chagas disease and monitor drug efficacy. MH is the
direct parasitological method of choice to identify congenital infection in newborns and
infants because of its high sensitivity and the small amount of blood needed [6]. Evaluation of
drug efficacy, on the other hand, commonly relies on negative conversion of parasitological
tests that detect anti-T.cruzi antibodies [29]. However negative seroconversion by conven-
tional serology can take years, or even decades, after treatment in older children and adults
and is therefore not an adequate treatment response endpoint [10,30].
While PCR may be more sensitive than MH in some centers, the current lack of standardi-
zation of the method across centers is a still unresolved issue. Furthermore, actual rate of false
Fig 4. Survival curve time to negative serology by age group: for ELISA; for IHA; and for F2/3.
https://doi.org/10.1371/journal.pntd.0007668.g004
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positives is still under debate and may vary among testing laboratories (and PCR methods
used), and other issues such as cost and instrument availability, and technical skills conspire to
limit the use of this technique at the moment.
In our cohort, most of the treated children younger than 2 years (74.3%) rapidly became
negative by MH and/or PCR, CS and F2/3-ELISA with an excellent correlation among all of
them, supporting their usefulness as markers of parasiticidal effect in this age group. Children
older than 2 years of age showed lower incidence of seroconversion but widespread CS and
F2/3-ELISA seroreduction coupled to early negative PCR results after treatment. Significant
reductions of T.cruzi antibody levels have been hypothesized to be a predictor of future nega-
tive seroconversion [22,30].
Previous published placebo-controlled trials in children [31,32] showed reductions of
approximately 20% in T.cruzi antibody levels by CS-ELISA at 12 months follow up in treated
pediatric patients. In contrast, placebo-treated patients showed persistent reactive serology
without modifications of antibody titers. A significant difference between the treatment and
placebo groups was apparent as early as 6 months after treatment. This was also observed in a
historical series of treated patients with acute vectorial infection where the treated group
showed a persistent decay in antibodies, while the untreated group showed no significant
changes in antibody titers and persistence of positive parasitological tests during follow-up
[33], suggesting that a decrease in antibody concentration is a marker of adequate treatment
response.
Persistent positive serology after treatment, in subjects with conversion to non-reactive
T.cruzi-PCR, could be justified by the permanence of an immune response generated by self-
antigens. Heart proteins may exhibit cross-reactivity with parasite surface antigens, a phenom-
enon known as molecular mimicry [34]. In other infections, after treatment, antigens remain
in phagocytic cells, dendritic cells and macrophages long after treatment, and immune mem-
ory cells can continue to produce antibodies and mount specific immune responses decades
after the infection or vaccination. In addition, carbohydrate determinants present in gastroin-
testinal and pulmonary microflora could stimulate lymphocytes previously primed by T.cruzi
epitopes, sustaining reactive serology in otherwise cured subjects [35].
Identification of novel and reliable post therapeutic markers is needed, such as surrogate
markers to identify absence or reduction of parasite load, which should be quicker and more
sensitive than seroconversion by conventional serology.
Using non-conventional serological techniques, i.e. highly sensitive and specific chemilu-
minescent ELISA using a purified trypomastigote glycoconjugate antigen (AT or F2/3 ELISA)
[32], the time to negative seroconversion was significantly faster for AT/F2-3 ELISA than for
the CS (ELISA, IHA).
In a previous study by our group [5], the kinetics of disappearance of conventional serology
and anti-F2/3 antibodies were compared in 21 patients with congenital CD after receiving
benznidazole treatment. In patients younger than 8 months, antibodies were undetectable by
both conventional serology and F2/3-ELISA soon after treatment. In older infants a negative
F2/3-ELISA result occurred earlier than for CS.
In our study these results were reinforced with a large cohort where F2/3-ELISA became
negative earlier than CS-ELISA. Consequently, a negative F2/3-ELISA should be considered as
a surrogate endpoint for assessment of positive response to treatment, particularly in those
patients with prolonged time of infection. However, usefulness of F2/3 ELISA is limited due to
the lack of standardized commercial kits which makes reproducibility of results difficult. Fur-
thermore, the fact that a sizable proportion of patients are already negative at the start of the
treatment decreases the population that may benefit from follow up with this method.
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PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007668 August 29, 2019 10 / 14
In an effort to obtain more sensitive parasitological assays, a T.cruzi-PCR strategy has been
developed to detect T. cruzi DNA in blood samples. Thus, primers have been designed for the
amplification of nuclear and kinetoplast T.cruzi-DNAs, both of which contain many repetitive
sequences that are highly suitable for T.cruzi-PCR detection [36].
Several studies have shown that T,cruzi-PCR is a more sensitive parasitological marker for
treatment failure than classical parasitological procedures [12,13,36,37,38,39].
Our study shows that PCR is an early marker of treatment response since PCR was negative
in 98.5% of patients at the end of treatment, remaining negative during long term follow-up.
These results are in line with previous reports from our group [12] and from other authors
[11,13,36,40].
In our cohort of congenital cases, negative PCR strongly correlated with seroreduction or
negative seroconversion by CS and F2/3-ELISA. This occurred in all patients in both the acute
and early chronic indeterminate phase of infection.
PCR provides a helpful clinical tool for early detection of treatment failure. As an example,
in 2 cases in our series, PCR remained positive after treatment and levels of T.cruzi antibodies
remained unchanged by CS and F2/3 ELISA, suggesting treatment failure given that these
patients lived in a non-endemic area (i.e. could not have suffered re-infection). The fact that
the mother of one of these patients later acknowledged that she had not administered the med-
ication further strengthens this point. The patients were later treated, one with nifurtimox and
the other one with benznidazol at standard doses for 60 days, with good therapeutic response,
and showed negative conversion of PCR and decrease in CS and F2/3 ELISA confirming that
these tests are sensitive both to treatment response and treatment failure.
Our study has some limitations, including lack of very long follow ups (eg. decades) to con-
firm that treatment response, as measured by serology and PCR, correlates with decreased
risks of cardiac involvement decades later. However, such prolonged follow up periods are
technically impossible at this stage. The absence of an untreated control group in our cohort
could be considered a limitation too, but, as mentioned before, there is extensive evidence
showing that patients that are not treated continue to have positive PCR and CS-ELISA titers
do not fall in time. This evidence has prompted laws and guidelines mandating treatment of
pediatric Chagas disease, precluding the inclusion of an untreated cohort in pediatric studies
(which would be considered unethical).
We concluded that the data reported here, used CS, F2/3 ELISA and molecular biology-
based laboratory tools (i.e. PCR) to demonstrate efficacy of chemotherapy in pediatric CD. We
believe it is vital to reinforce the need to screen all pregnant women living in or emigrating
from endemic areas, in order to provide their newborns with an early accurate diagnosis for
more successful treatment outcome [41].
Finally, these results provide support for the scaling up of diagnosis and access to standard
regimens of benznidazole.
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